Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608270 | 0.90 | PGR (0.62) | PGRHRH3FPR2PROKR1CYP11B1 | |
| SCHEMBL4609190 | 0.88 | PGR (0.53) | PGRHRH3FPR2PROKR1CYP11B1 | |
| SCHEMBL4624084 | 0.88 | PGR (0.52) | PGRHRH3FPR2PROKR1 | |
| SCHEMBL4609100 | 0.85 | PGR (0.49) | PGRFPR2PROKR1 | |
| SCHEMBL4608798 | 0.85 | PGR (0.48) | PGRHRH3 | |
| SCHEMBL4709063 | 0.83 | PGR (0.47) | PGRHRH3SIGMAR1CYP11B1CYP11B2 | |
| SCHEMBL4609093 | 0.82 | PGR (0.46) | PGRHRH3SIGMAR1 | |
| SCHEMBL4609487 | 0.81 | PGR (0.46) | PGRHRH3CYP11B1CYP11B2 | |
| SCHEMBL4959617 | 0.81 | PGR (0.50) | PGRCYP11B1CYP11B2KDM4E | |
| SCHEMBL13889242 | 0.81 | PGR (0.48) | PGRHRH3CYP11B1CYP11B2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | claimed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | claimed |
| EP-1948615-A2 | COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2008-07-30 | — | — | EP | claimed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | claimed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | claimed |
| WO-2007054770-A2 | PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE | PFIZER LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | claimed |
| EP-1948615-B1 | Pyrazole derivatives useful for the treatment of gynaecological diseases | PFIZER LTD (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-7425569-B2 | 1H-pyrazoles useful in therapy | PFIZER INC (US) | 2008-09-16 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | BRADLEY PAUL A | 2008-04-10 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| US-7309712-B2 | 1H-pyrazoles useful in therapy | PFIZER LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| WO-2007054770-A2 | PYRAZOLE DERIVATIVES AND THEIR MEDICAL USE | PFIZER LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105909-A1 | Compounds useful in therapy | PFIZER INC. | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105909-A1 | Compounds useful in therapy | GNRHR, OPRK1, CBR3 | PGR 155/4885HRH3 116/4885FPR2 1416/4885 |
| US-20080085919-A1 | 1H-Pyrazoles Useful In Therapy | CBR3, GNRHR, RXFP3 | PGR 87/4885HRH3 99/4885FPR2 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.